Oramed Pharmaceuticals Inc. (ORMP)
NASDAQ: ORMP · Real-Time Price · USD
2.420
+0.050 (2.11%)
Oct 10, 2025, 2:59 PM EDT - Market open

Oramed Pharmaceuticals Stock Forecast

Stock Price Forecast

There is currently no analyst price target forecast available for Oramed Pharmaceuticals.

Price Target: $ (0.00%)
Analyst Consensus: n/a
TargetLowAverageMedianHigh
Pricen/an/an/an/a
Changen/an/an/an/a

Analyst Ratings

There are currently no analyst ratings available for Oramed Pharmaceuticals.

Recommendation Trends

RatingApr '24May '24Jun '24Jul '24Aug '24Sep '24
Strong Buy000000
Buy000000
Hold211110
Sell000000
Strong Sell000000
Total211110

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
HC Wainwright & Co.
HC Wainwright & Co.
Hold
Reiterates
n/a
HoldReiteratesn/an/aSep 9, 2024
HC Wainwright & Co.
HC Wainwright & Co.
Hold
Reiterates
n/a
HoldReiteratesn/an/aMay 20, 2024
Canaccord Genuity
Canaccord Genuity
Hold
Maintains
$3$2
HoldMaintains$3$2-17.36%May 17, 2023
HC Wainwright & Co.
HC Wainwright & Co.
Hold
Downgrades
n/a
HoldDowngradesn/an/aJan 17, 2023
Canaccord Genuity
Canaccord Genuity
Hold
Downgrades
n/a
HoldDowngradesn/an/aJan 12, 2023
More Analyst Ratings

Financial Forecast

Revenue This Year
2.04M
Revenue Next Year
n/a
from 2.04M
EPS This Year
-0.35
from -0.48
EPS Next Year
n/a
from -0.35
Fiscal YearFY 2021FY 2021FY 2022FY 2023FY 2024FY 2025
Period EndingAug 31, 2021Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025
Revenue
2.70M2.71M2.70M1.34M-2.04M
Revenue Growth
-0.33%0.33%-0.33%-50.43%--
EPS
-0.78-0.94-0.940.14-0.48-0.35
EPS Growth
------
Forward PE
------
No. Analysts
-----3
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue2025
High2.1M
Avg2.0M
Low2.0M

Revenue Growth

Revenue Growth2025
High-
Avg-
Low-

EPS Forecast

EPS2025
High-0.36
Avg-0.35
Low-0.33

EPS Growth

EPS Growth2025
High-
Avg-
Low-
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.